Learning Objectives

At the conclusion of this session, the participant should be able to:

• explain the use of SGLT2is in both diabetic and non-diabetic patients.
• understand regional and state-by-state differences in SGLT2i prescription rates to Medicaid patients across the United States.
• discuss the impact of state Medicaid policy on patient care. 

Speakers:

Khevna Joshi, BA, Student, Geisinger Commonwealth School of Medicine - nothing to disclose. 

Conor Banta, BA, Student, Geisinger Commonwealth School of Medicine - nothing to disclose. 

Moderator:

Brian Piper, PhD, Staff, Geisinger Commonwealth School of Medicine, Geisinger - nothing to disclose.